The New Disruptor In The Cell Therapy Landscape: How Will Hospital-Developed CAR-T Impact The European Landscape?

By Pedro Ornelas, Cody Powers, Sankalp Sethi, and Adil Refai

Chimeric antigen receptor therapy (CAR-Ts) have significant investment and innovation potential, but pharma companies are still learning to manage bottlenecks such as reimbursement challenges, long turnaround times and manufacturing delays. “Hospital-developed” CAR-Ts are CAR-Ts that have their clinical programs sponsored, researched, manufactured and administered by academic institutions without partnership with pharmaceuticals. They have been generating significant excitement due to their hypothesized ability to deliver at lower costs and reduce turnaround times (TaT). 

Despite the buzz and regulatory advances, many hurdles remain — primarily scalability potential — that will limit the impact of hospital-developed CAR-T on the ecosystem and hinder their competitive advantage over pharmaceutical companies. Through financial modeling of hospital-developed CAR-T manufacturing costs, interviews with European key opinion leaders (KOLs) and a literature review, learn why hospitals are developing their own CAR-T products, how scalable hospital-developed CAR-T products are likely to be, how the emergence of hospital-developed CAR-T will impact the commercial strategy of pharmaceutical companies, and more.